Three days after completing its acquisition of US biotech Aimmune Therapeutics, Inc., Nestle Health Science's strategy of expanding in the food allergies space is already paying dividends with regulators in Europe recommending approval of Palforzia, the first treatment for children with peanut allergies.
Aimmune's Peanut Immunotherapy Palforzia Gets CHMP Backing
Company Bought By Nestlé Health Science Days Earlier
Palforzia will almost certainly be the first treatment to get the green light for peanut allergy in Europe and its new owner will be hoping for a more successful launch than has been seen in the US.
More from New Products
More from Scrip
• By
While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
• By
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.